Form 4: Bio-Techne Director Amy E. Herr Reports Stock and Option Transactions
SEC Form 4 Filing
Director Amy E. Herr reports acquisition and disposal of Bio-Techne Corp stock and stock options.
Summary
- On February 3, 2025, Amy E. Herr, a director of Bio-Techne Corp, reported transactions involving the company's stock and stock options.
- Herr acquired 1,040 shares of common stock at $0 and disposed of 1,040 shares of common stock.
- She also acquired 2,415 stock options with an exercise price of $72.05, expiring on February 3, 2035.
- Additionally, she acquired 115 restricted stock units.
- Herr indirectly owns various stock options and restricted stock units through a significant other.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document is a standard regulatory filing detailing stock and option transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules of the restricted stock units and stock options suggest a continued alignment of the director's interests with the company's long-term performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Comparison to Industry Standards
- Stock option grants and restricted stock units are common forms of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholder value.
- Companies like Thermo Fisher Scientific and Danaher also utilize similar equity-based compensation plans for their executives.
- The vesting schedules and exercise prices of the options are typical for such grants, designed to reward long-term value creation.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly diluting the stock base as options vest and shares are issued.
- The vesting schedules of the equity grants incentivize the director to contribute to the company's long-term success, benefiting all stakeholders.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of earliest transaction: Acquisition and disposal of common stock and acquisition of stock options and restricted stock units. |
| 02/07/2025 | Date of filing the Form 4. |
| 02/03/2035 | Expiration date of stock options acquired on 02/03/2025. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.